Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
152 words
A fusion polypeptide comprising, as at least part of the N-terminal portion thereof, an N-terminal portion of HSA or a variant thereof and, as at least part of the C-terminal portion thereof, another polypeptide except that, when the said N-terminal portion of HSA is the 1-n portion where n is 369 to 419 or a variant thereof then the said polypeptide is (a) the 585 to 1578 portion of human fibronectin or a variant thereof, (b) the 1 to 368 portion of CD4 or a variant thereof, (c) platelet derived growth factor or a variant thereof, (d) transforming growth factor β or a variant thereof, (e) the 1-261 portion of mature human plasma fibronectin or a variant thereof, (f) the 278-578 portion of mature human plasma fibronectin or a variant thereof, (g) the 1-272 portion of mature human von Willebrand's Factor or a variant thereof, or (h) alpha-1-antitrypsin or a variant thereof.
Claim 2
Dependent Claim
152 words
A fusion polypeptide comprising, as at least part of the N-terminal portion thereof, an N-terminal portion of HSA or a variant thereof and, as at least part of the C-terminal portion thereof, another polypeptide except that, when the said N-terminal portion of HSA is the 1-n portion where n is 369 to 419 or a variant thereof then the said polypeptide is (a) the 585 to 1578 portion of human fibronectin or a variant thereof, (b) the 1 to 368 portion of CD4 or a variant thereof, (c) platelet derived growth factor or a variant thereof, (d) transforming growth factor β or a variant thereof, (e) the 1-261 portion of mature human plasma fibronectin or a variant thereof, (f) the 278-578 portion of mature human plasma fibronectin or a variant thereof, (g) the 1-272 portion of mature human von Willebrand's Factor or a variant thereof, or (h) alpha-1-antitrypsin or a variant thereof.
Claim 3
Dependent Claim
26 words
A fusion polypeptide according to Claim 1 additionally comprising at least one N-terminal amino acid extending beyond the portion corresponding to the N-terminal portion of HSA.
Claim 4
Dependent Claim
25 words
A fusion polypeptide according to Claim 1 or 2 wherein there is a cleavable region at the junction of the said N-terminal or C-terminal portions.
Claim 5
Dependent Claim
30 words
A fusion polypeptide according to any one of the preceding claims wherein the said C-terminal portion is the 585 to 1578 portion of human plasma fibronectin or a variant thereof.
Claim 6
Dependent Claim
25 words
A transformed or transfected host having a nucleotide sequence so arranged as to express a fusion polypeptide according to any one of the preceding claims.
Claim 7
Dependent Claim
27 words
A process for preparing a fusion polypeptide by cultivation of a host according to Claim 5, followed by separation of the fusion polypeptide in a useful form.
Claim 8
Dependent Claim
16 words
A fusion polypeptide according to any one of Claims 1 to 4 for use in therapy.